## Supplementary digital content

Supplementary Table 1. Overview of short-term studies

|  |  |  |
| --- | --- | --- |
| **Vector**  **Study 331-10-231**  **(NCT01396421)** | **Beacon**  **Study 331-10-230**  **(NCT01393613)** | **Lighthouse**  **Study 14644A**  **(NCT01810380)** |
| **636 patients treated** | **674 patients treated** | **464 patients treated** |
| Fixed dosing | Fixed dosing | Flexible dosing |
| Brexpiprazole 0.25 mg/day (N=90)  Brexpiprazole 2 mg/day (N=182)  Brexpiprazole 4 mg/day (N=180)  Placebo (N=184) | Brexpiprazole 1 mg/day (N=120)  Brexpiprazole 2 mg/day (N=186)  Brexpiprazole 4 mg/day (N=184)  Placebo (N=184) | Brexpiprazole 2–4 mg/day (N=150)  Placebo (N=161)  Quetiapine XR 400–800 mg/day (N=153) |

Supplementary Table 2. Overview of long-term studies

|  |  |
| --- | --- |
| **Zenith**  **Study 331-10-237**  **(NCT01397786)** | **Lighthouse extension**  **Study 14644B**  **(NCT01810783)** |
| **1031 patients treated**  De novo (N=224)  Beacon prior brexpiprazole (N=219)  Beacon prior placebo (N=67)  Vector prior brexpiprazole (N=217)  Vector prior placebo (N=61)  Equator prior brexpiprazole (N=169)  Equator prior placebo (N=74) | **209 patients treated**  Prior brexpiprazole (N=66)  Prior placebo (N=64)  Prior quetiapine (N=79) |
| Flexible dosing | Flexible dosing |
| Brexpiprazole 1–4 mg/day | Brexpiprazole 1–4 mg/day |

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Sex** | **Females** | | | | | | **Males** | | | | | |
| **Baseline status** | **Normal** | | | **>1x ULN** | | | **Normal** | | | **>1x ULN** | | |
| **Treatment** | **Placebo** | **Brexpiprazole 2 mg** | **Brexpiprazole 4 mg** | **Placebo** | **Brexpiprazole 2 mg** | **Brexpiprazole 4 mg** | **Placebo** | **Brexpiprazole 2 mg** | **Brexpiprazole 4 mg** | **Placebo** | **Brexpiprazole 2 mg** | **Brexpiprazole 4 mg** |
| **Baseline; mean (median) [n]** | 10.60 (9.87) [104] | 9.66 (8.62) [114] | 11.33 (9.44) [111] | 68.47 (48.38) [35] | 79.42 (52.85) [21] | 60.43 (50.42) [29] | 6.68 (6.47)  [170] | 6.12 (5.39)  [171] | 6.83 (6.21)  [164] | 25.04 (21.11) [59] | 27.51 (20.13) [61] | 24.30 (20.65) [60] |
| **Change Week 6; mean (median) [n]** | -0.43 (-0.91)  [56] | 5.93 (4.46)  [79] | 6.74 (5.65)  [75] | -41.48 (-34.25) [21] | -48.13 (-28.67) [16] | -28.69 (-26.13) [23] | 0.44 (-0.17) [112] | 2.47 (1.84)  [115] | 2.85 (1.68)  [108] | -10.25(-11.84) [37] | -14.38 (-11.21) [41] | -10.38 (-8.07) [43] |
| ULN: upper limit of normal | | | | | | | | | | | | |

Supplementary Table 3: Fixed-dose, short-term studies – mean changes from baseline by dose, sex and baseline prolactin status